Valirx Share Discussion Threads

[aimmafia] 02/11/2021 07:37

First payment could be 50k for all you know or even shares

[aimmafia] 02/11/2021 07:37

Well Im still out on the bell. I thought there would be an upfront payment of at least 2 - 5 million

[ks66] 02/11/2021 07:34

But you cannot sell a bean above 60p

[dope007] 02/11/2021 07:33

Good news and another step forward. No fund raising needed at all due to the first payment

[aimmafia] 02/11/2021 07:30

Although it looks like it's going to open above 60!!!

[aimmafia] 02/11/2021 07:29

I am out on the bell and putting the rest into #BEN

[aimmafia] 02/11/2021 07:28

Peanuts, because there is only a couple of million available before 2023

[glasswala] 02/11/2021 07:20

How much due before end of 2021?? They kept that quitely hidden. Why not tell us?? Can't be a lot thats why!!

[bonzo] 02/11/2021 07:08

The first payments due by end 2021

[aimmafia] 02/11/2021 07:04

Ouch! Only a letter of intent, no payments until 2023 - disaster! Im out

[uknighted] 02/11/2021 07:04

Signs Letter of Intent to Sub-License VAL201



London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, announces today it has entered into a non-binding letter of intent ("LOI") with TheoremRx Inc. ("TheoremRx"), a recently incorporated company, a next generation drug development Company, to enter into a licence agreement on pre-agreed terms to sub-license ValiRx's legacy asset VAL201 for development in the treatment of cancer (the "Licence Agreement"). Completion of the Licence Agreement is subject to, inter alia, the successful fundraise by TheoremRx.

TheoremRx is private US-based oncology company focused on the discovery and development of new treatments that will benefit patients suffering from cancer. TheoremRx has established a highly integrated approach for the discovery, development and manufacture of peptide and small molecule drugs that modulate targets of clinical interest.

Under this proposed Licence Agreement, TheoremRx will obtain a worldwide licence to ValiRx's VAL201 intellectual property for a novel peptide targeting SRC kinase targeting oncology indications. ValiRx will retain the rights to develop the VAL201 peptide for non-oncology indications, including VAL301 for endometriosis. Subject to successful market authorisation, the potential value of the deal would be in excess of US$61M plus royalties for the first cancer indication alone. Each oncology indication successfully developed to by TheoremRx will generate up to $37.5M of additional value to ValiRx. The proposed deal structure comprises payments on signature of the Licence Agreement plus fees and near-term milestones totalling US$2.2M before the end of 2023, milestones on further clinical and commercial development events, and royalties. The first payments are expected by the end of 2021.

As part of the deal, TheoremRx will enter into a service contract with ValiRx to provide consulting services to TheoremRx to aid technology transfer, formulation for patent extension and continued clinical development of VAL201.

The LOI details a period of exclusivity during which TheoremRx will complete its due diligence on the scientific and commercial attributes of VAL201, during which ValiRx is restricted from continuing to market the programme to other parties. Completion of the Licence Agreement is also subject to terms and conditions at closing.

The LOI and proposed Licence Agreement therefore remain non-binding and there is no guarantee that this Licence Agreement will be executed or that it will generate material revenues within the expected timeframe or at all.

Dr Suzy Dilly, CEO of ValiRx commented: "Selecting a commercial partner for VAL201 with the right skills, experience and commitment has been a high priority for ValiRx. I am delighted that the team at TheoremRx has really taken the time to understand the science, the additional development needs and the commercial opportunity for VAL201 in oncology. I am looking forward to seeing the programme progress efficiently through the clinical development plan in their hands."

Dr Ken Sorensen, Chairman of TheoremRx stated: "We are very excited to be pursuing an agreement with ValiRx, a company with extensive and proven experience in research and drug development. We look forward to working towards a final agreement and seeing this technology occupy a preeminent position in the market for treating different cancers."

[porky9] 02/11/2021 01:37

Terrific Tuesday – 74p to 85p Inbound

OK, OK, I hear you scream not another bloody Porky prediction, well guy’s you are going to get it anyway… I just can’t sit around with some of these two-bit traders posting, who have done zero research into what this business is about yet feeling smug they have tried to save threepence on an already battered down share price that languishes at this pathetically low valuation.

£ 34m mcap at close Monday, give me strength

I’m allowing for the fact that Share Prices don’t go up in straight lines, I’m allowing for traders and bedwetters with their fingers on the sell button taking small gains but I’m predicting for a BIG blue day today. At least a 9p ADD today if not more and climbing this week towards that 74-85p range.

To get to peer average in one hit we would have to add +36% today from 54p. Not impossible, we would head the leader’s board. The valuation here is like a coiled spring, you really can’t hold it down much longer before we absolutely explode to new heights.

Either way, we are going onto that 74p to 85p range as minimum, watch this space
If information on deals starts to leak, we will go materially higher a lot sooner and I think that could happen here. I saw it on RedX, the day before the licensing deal was announced, amazingly the company value went up by £ 30m in one day, what a coincidence that was :) the following 7 days they added 100m to the mcap and every chance we could see that sort of rise here.

IMO for what its worth, in the Biotech space if they get it right, the valuation’s just skyrocket. With Valirx, I don’t think its just a case of getting right once, I think we have a high chance of 201, 301 and 401 ultimately securing licensing. Three times over, wouldn’t that be something….

Time will tell, here’s to a terrific Tuesday

GLA

[porky9] 02/11/2021 00:44

Red Hot Buy - Valuation Re-Rate

What we are seeing is a rerate of the company

We have been materially undervalued for so long that many have just got used to it but it’s as clear as day to see when you compare us to our peers.

My stance remains at 74p to 85p pre licensing as continually stated. 80p being £52m mcap bang on the peer group average and significantly higher after deals.
Let’s explore this further based on deals.

Currently we can’t know what Valirx are negotiating behind the scenes or their success in negotiations. We can only speculate. What we do know is that taking curved balls out of the equation, both 201 and 301 are packaged ready to go and so is possibly 401 as its a reformulated generic drug with a much shorter route to market. So potentially three horses in the stable ready to run.

From my own independent research and please do your own, the Prostate cancer drugs market last year, where 201 is positioned, was worth $11.2bn USD and growing

Meanwhile, the Endometriosis drugs market where 301 is positioned, is worth just short of a $2bn USD market size with expected growth to $2.2bn by 2027

The pancreatic cancer drugs market last year, where 401 is positioned, was worth $2.6bn last year and expected to rise to almost $3.8 by 2027 So we are talking big numbers here.

Our mcap tonight at 53p is still a mere £ 34m, I want to post that again because some are just not getting it, we are valued at £ 34m – This is not just materially undervalued, it is plain farcical.

Now we have explored from our peer group Sareum at £ 223m mcap and I believe we are potentially stronger and can overtake this Biotech. Mentioned a couple of days back was also RedX Pharma from our peer group, which spookily is also valued at £ 223m mcap.

RedX secured a back loaded $200m licensing deal on milestones including tiered royalties in mid-single digit percentages, based on any future net sales. The upfront was $10m payment. On the day of the announcement the deal boosted their mcap value, marked up immediately by £ 30m and over the following 7 days the share price rallied by a further £ 100m value.

Now I’m not saying Valirx will do the same, all deals are different and have their merits but come on.

We have potentially THREE deals here to be done not just one. I could be totally wrong in my calculation but If I were a betting man, I would say 201 alone could be worth £200m and £10m down like the RedX deal. As such our market cap should run towards same, if it did, we would be looking at a circa £ 160m mcap value or £ 2.46 share price NOT a 54p one with the other deals still to come.

The market currently wants to see proof of deals. I believe we will see that shortly and when we do, we will see that step change in the share price and further rally, in the meantime the MMs are getting prepared for it.

IMO It is going to happen, this is why I’m a buyer and adding at this level, a total no brainer.

GLA

[412069] 01/11/2021 11:39

Looking like Porkys getting it correct over the doomers.

[nico115] 01/11/2021 11:30

Can't see a deal in December So we must be a few days or 4weeks max away from a 201 deal Bring it on

[reidy66] 01/11/2021 11:20

Excellent rise today after a stalemate opening

[porky9] 01/11/2021 03:44

RED HOT BUY
This is the final call now....
Having the confidence that Valirx will deliver and buying now at a major discount ahead of news OR waiting to see if they deliver and buying at a premium after.

Trending nicely towards peer average range 74-85p


This will separate the men from the boys... GLA

[porky9] 31/10/2021 14:00

Curved Balls Landing to Take us Higher

Much discussion surrounding 201 and 301 which I think most agree are the forerunners for licensing.

However, let’s not forget 401:
VAL401 has a much shorter route to market due to the nature of it as a reformulated generic drug and as such it’s possible a deal of sorts could be concluded shortly. Now this one is very much in the hands of the partner Black Cat Bio.

We are very much in the dark on this one and working at their pace, but I don’t think its unreasonable for shareholders to expect an update on 401 soon. This could be something that also boosts us.

Then we come onto BC201:
BC201 incorporates the VAL201 peptide as a component of a possible treatment for patients suffering severe symptoms of Covid-19. It also continues to be developed for treatment of patients with viral-induced sepsis and other diseases with similar immune system driven causes.

Now this one is in a consortium between ValiRx, OncoLytika and Black Cat Bio, so again, I would expect some sort of update on that one soon regarding this project and its outlook.

Finally, we can expect a number of other new projects will be added once upfront licensing fees land as it will give them significantly more financial flexibility.

They mentioned during the presentation evaluating over 65 projects this last year and activity is continuing.

The reason that this will be the transformative year for Valirx is because with the first deals over the line they then have the capacity to exponentially expand with far more projects and this is what we will see going into 2022 and beyond.

Investing now in Valirx is possibly the best time, with the best risk reward ratio than at any other time in its history.

Remaining as Bullish as ever here.

GLA

[porky9] 31/10/2021 12:46

201 and 301 Deals – Stratospheric share price Rise Inbound

The way I see it we are going to see 201 come over the line before the end of this year as confirmed. It’s going to happen.

I also believe that 301 can’t be far behind either. Firstly, 301 uses the same ingredient as 201 so safety and tolerability data from 201 is being carried over and secondly, 301 entered the evaluation period for its effectiveness against endometriosis at the start of May 2020 so it will have been with the Japanese Bio for 18mths on Monday. I don’t know what the milestone dates are, but 18 months would feel like a dam good milestone period to me? So could be any moment now.

Now I’m not saying we are going to come into major deal confirmations on Monday, it could happen anytime between now and most likely up to 6 weeks, but it’s going to happen.

On Friday after two days retrace, we closed at just shy of £ 33m mcap, I genuinely believe that the licensing deal for either 201 or 301 will be at multiples of this value. If both come in close to each other the share price uplift will be off the scale imo and happen quickly and surely must place us in the £150m to £200m mcap value range possibly up to £300m as I see it.

If Sereum can warrant a £215m mcap I am dam sure Valirx can exceed it.

There won’t be any, oh I was waiting to save threepence on the share price but can still catch it quick. The market will just open materially higher and rally from there.

From my own independent research and please do your own, the Prostate cancer drugs market last year, where 201 is positioned, was worth $11.2bn USD and growing

Meanwhile, the Endometriosis drugs market where 301 is positioned, is worth just short of a $2bn USD market size with expected growth to $2.2bn by 2027
So, we are talking material numbers here.

Now, if anyone wants to try and trade this be my guest, I’m building a fairly sizable position here so one could argue that I’m in a better position than most to trade but, there is no way on this planet I’m going to risk being out when an update lands, we are too close to the line now.

As such I think other investors will also realise this is the case and we will see positions being retaken next week. Its going to get interesting.

GLA

[average down mug] 31/10/2021 09:24

🤡☝A039;Just expect another tr1 from nick and news you need to take this to the next level! Don’t see a big drop personally not in GlA

[porky9] 30/10/2021 10:00

It would be utter madness to sell to try and time a buy back in. Not easy to buy volume either.
The upside is stratospheric from here and the market knows it, one contract will be at multiples of the current market cap.
Personally, I’m still expecting these at peer average £52m mcap 80p prior to first license and it trade in the 74p to 85p range. In fact I believe we are above average hence Zac Mir at 90p might just have called it right. Time will tell soon enough but I’m certainly not selling mine at this low mcap.
A few other updates are also due pre main licensing news, could be an interesting week, GLA

[forkie 12] 29/10/2021 16:45

🤕🤕

[412069] 29/10/2021 15:42

Not happening at the mo L2’s 5 v 1 so come back Monday to see if the news has come in.

[arab3] 29/10/2021 15:31

IF. !!!!!!!! Lol